Jubilant Pharmova's Montreal facility completes USFDA audit

Jubilant Pharmova Limited announced today, November 4, 2025, that the United States Food and Drug Administration (USFDA) has concluded an audit of Jubilant HollisterStier General Partnership (JHSGP)'s contract manufacturing facility in Montreal, Canada. The audit, completed on November 3, 2025, resulted in 9 observations being issued by the USFDA. JHSGP, which is jointly owned by subsidiaries of Jubilant Pharma Limited, will submit an action plan in response to these observations.

Jubilant Pharma Limited (JPL), a wholly-owned subsidiary of Jubilant Pharmova, is an integrated global pharmaceutical company with a network of 45 radiopharmacies in the US, and manufacturing facilities catering to regulated markets including the USA and Europe. Jubilant Pharmova itself is a global entity involved in various pharmaceutical businesses, including Radiopharma, Allergy Immunotherapy, and CDMO Sterile Injectables.